Alpha-gal glycosphingolipid - Agalimmune

Drug Profile

Alpha-gal glycosphingolipid - Agalimmune

Alternative Names: AGI-134; Beta-galactosidase glycosphingolipid - Agalimmune; Glycosphingolipid beta-galactosidase immunotherapy

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator University of Massachusetts Medical School
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant melanoma; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma in USA (Intratumoural, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (Intratumoural, Injection)
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top